Lynk Pharmaceuticals Co., Ltd., a China-based clinical stage company, announced on Monday that it has dosed the first subject in a phase II clinical trial of its innovative drug LNK01003 in Ulcerative Colitis (UC).

The Phase II clinical study is intended to assess the efficacy and safety of LNK01003 in patients with active UC.

LNK01003is an oral small molecule JAK inhibitor with intestine-restricted properties and a potential first-in-class treatment for UC and other related diseases.